Differential Impact of Admission C-Reactive Protein Levels on 28-Day Mortality Risk in Patients With ST-Elevation Versus Non–ST-Elevation Myocardial Infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry)

      The present study investigated the association between C-reactive protein (CRP) on admission independently and in combination with troponin and short-term prognosis in an unselected sample of patients with acute myocardial infarction (AMI) from the community. The study population consisted of 1,646 patients aged 25 to 74 years who were consecutively hospitalized with AMI within 12 hours after symptom onset. They were divided into the 2 groups of CRP positive (n = 919) or CRP negative (n = 727) with respect to admission CRP (cutoff ≤0.3 mg/dl). CRP-positive patients had significantly more in-hospital complications and a higher 28-day case-fatality rate (9.6% vs 3.4%; p <0.0001). Troponin at admission (n = 1,419) also correlated with 28-day case-fatality rate (troponin-negative 3.4% vs troponin-positive patients 8.0%; p <0.002). Multivariable analysis showed that both troponin positivity and CRP positivity were associated with a 2-fold (adjusted odds ratio 1.99, 95% confidence interval 1.15 to 3.44; adjusted odds ratio 2.05, 95% confidence interval 1.09 to 3.84, respectively) increased risk of dying within 28 days after the acute event for all patients with AMI. Stratifying by AMI type showed that in patients with ST-elevation myocardial infarction (STEMI), troponin positivity, but not CRP positivity, independently predicted 28-day case fatality. In patients with non-STEMI, CRP positivity, but not troponin positivity, predicted outcome. In conclusion, admission CRP was a powerful parameter for risk stratification of patients with AMI. Stratification by AMI type and troponin showed that CRP was a better short-term risk predictor for patients with non-STEMI, and troponin was, for patients with STEMI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Toss H.
        • Lindahl B.
        • Siegbahn A.
        • Wallentin L.
        • The FRagmin during InStability in Coronary artery disease (FRISC) Study Group
        Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease.
        Circulation. 1997; 96: 4204-4210
        • Lindahl B.
        • Toss H.
        • Siegbahn A.
        • Venge P.
        • Wallentin L.
        • The FRagmin during InStability in Coronary artery disease (FRISC) Study Group
        Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease.
        N Engl J Med. 2000; 343: 1139-1147
        • Heeschen C.
        • Hamm C.W.
        • Bruemmer J.
        • Simoons M.L.
        • The Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment (CAPTURE) Investigators
        Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis.
        J Am Coll Cardiol. 2000; 35: 1535-1542
        • WHO MONICA Project Principal Investigators
        World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration.
        J Clin Epidemiol. 1988; 41: 105-114
        • Kuch B.
        • Bolte H.D.
        • Hörmann A.
        • Meisinger C.
        • Löwel H.
        What is the real hospital mortality from acute myocardial infarction?.
        Eur Heart J. 2002; 23: 714-720
        • Meisinger C.
        • Hörmann A.
        • Heier M.
        • Kuch B.
        • Löwel H.
        Admission blood glucose and adverse outcomes in non-diabetic patients with myocardial infarction in the reperfusion era.
        Int J Cardiol. 2006; 113: 229-235
        • Alpert J.S.
        • Thygesen K.
        • Antman E.
        • Bassand J.P.
        Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.
        J Am Coll Cardiol. 2000; 36: 959-969
        • Kuch B.
        • von Scheidt W.
        • Kling B.
        • Heier M.
        • Hörmann A.
        • Meisinger C.
        Characteristics and outcome of patients with acute myocardial infarction according to presenting electrocardiogram (from the MONICA/KORA Augsburg Myocardial Infarction Registry).
        Am J Cardiol. 2007; 100: 1056-1060
        • Rebuzzi A.G.
        • Quaranta G.
        • Liuzzo G.
        • Caligiuri G.
        • Lanza G.A.
        • Gallimore J.R.
        • Grillo R.L.
        • Cianflone D.
        • Biasucci L.M.
        • Maseri A.
        Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris.
        Am J Cardiol. 1998; 82: 715-719
        • Tomoda H.
        • Aoki N.
        Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction.
        Am Heart J. 2000; 140: 324-328
        • de Winter R.J.
        • Heyde G.S.
        • Koch K.T.
        • Fischer J.
        • van Straalen J.P.
        • Bax M.
        • Schotborgh C.E.
        • Mulder K.J.
        • Sanders G.T.
        • Piek J.J.
        • Tijssen J.G.
        The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty.
        Eur Heart J. 2002; 23: 960-966
        • Sanchez P.L.
        • Palacios I.F.
        • Pobon P.
        • Santos I.
        • Rodriguez M.V.
        • Villacorta E.
        • Martin-Moreiras J.
        • Cruz I.
        • Martin-Luengo C.
        Relationship between C-reactive protein and the electrocardiographic pattern on admission in patients with acute coronary syndrome.
        Cardiology. 2005; 104: 45-50
        • Haverkate F.
        • Thompson S.G.
        • Pyke S.D.
        • Gallimore J.R.
        • Pepys M.B.
        • The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
        Production of C-reactive protein and risk of coronary events in stable and unstable angina.
        Lancet. 1997; 349: 462-466
        • van der Wal A.C.
        • Becker A.E.
        • van der Loos C.M.
        • Das P.K.
        Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.
        Circulation. 1994; 89: 36-44
        • Moghbeli N.
        • Kirtane A.J.
        • Ray K.K.
        • Murphy S.A.
        • Gibson C.M.
        • Braunwald E.
        • Cannon C.P.
        • TIMI Study Group
        C-Reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial).
        Am J Cardiol. 2005; 96: 635-638
        • Ridker P.M.
        • Buring J.E.
        • Cook N.R.
        • Rifai N.
        C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.
        Circulation. 2003; 107: 391-397
        • Lindahl B.
        • Venge P.
        • Wallentin L.
        Relation between troponin T and the risk of subsequent cardiac events in unstable coronary disease: the FRISC Study Group.
        Circulation. 1996; 93: 1651-1657
        • Ohman E.
        • Armstrong P.
        • Christenson R.
        • Granger C.B.
        • Katus H.A.
        • Hamm C.W.
        • O'Hanesian M.A.
        • Wagner G.S.
        • Kleiman N.S.
        • Harrell Jr., F.E.
        • Califf R.M.
        • Topol E.J.
        Cardiac troponin T levels for risk stratification in acute myocardial ischemia.
        N Engl J Med. 1996; 335: 1333-1341
        • Hamm C.
        • Ravkilde J.
        • Gerhardt W.
        • Jørgensen P.
        • Peheim E.
        • Ljungdahl L.
        • Goldmann B.
        • Katus H.A.
        The prognostic value of serum troponin T in unstable angina.
        N Engl J Med. 1992; 327: 146-150
        • Foussas S.G.
        • Zairis M.N.
        • Makrygiannis S.S.
        • Manousakis S.J.
        • Anastassiadis F.A.
        • Apostolatos C.S.
        • Patsourakos N.G.
        • Glyptis M.P.
        • Papadopoulos J.K.
        • Xenos D.C.
        • et al.
        The significance of circulating levels of both cardiac troponin I and high-sensitivity C reactive protein for the prediction of intravenous thrombolysis outcome in patients with ST-segment elevation myocardial infarction.
        Heart. 2007; 93: 952-956
        • Kurowski V.
        • Hartmann F.
        • Killermann D.P.
        • Giannitsis E.
        • Wiegand U.K.
        • Frey N.
        • Müller-Bardorff M.
        • Richardt G.
        • Katus H.A.
        Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction.
        Crit Care Med. 2002; 30: 2229-2235
        • Giannitsis E.
        • Müller-Bardorff M.
        • Lehrke S.
        • Wiegand U.
        • Tölg R.
        • Weidtmann B.
        • Hartmann F.
        • Richardt G.
        • Katus H.A.
        Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction.
        Circulation. 2001; 104: 630-635
        • James S.K.
        • Armstrong P.
        • Barnathan E.
        • Califf R.
        • Lindahl B.
        • Siegbahn A.
        • Simoons M.L.
        • Topol E.J.
        • Venge P.
        • Wallentin L.
        • GUSTO-IV-ACS Investigators
        Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome.
        J Am Coll Cardiol. 2003; 41: 916-924
        • Celik T.
        • Iyisoy A.
        • Kursaklioglu H.
        • Turhan H.
        • Kilic S.
        • Kose S.
        • Amasyali B.
        • Isik E.
        The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.
        Coron Artery Dis. 2005; 16: 293-299
        • Zairis M.N.
        • Manousakis S.J.
        • Stefanidis A.S.
        • Papadaki O.A.
        • Andrikopoulos G.K.
        • Olympios C.D.
        • Hadjissavas J.J.
        • Argyrakis S.K.
        • Foussas S.G.
        C-Reactive protein levels on admission are associated with response to thrombolytic and prognosis after ST-segment elevation acute myocardial infarction.
        Am Heart J. 2002; 144: 782-789
        • Canale M.L.
        • Stroppa S.
        • Caravelli P.
        • Petronio A.S.
        • Mariotti R.
        • Mariani M.
        • Balbarini A.
        • Barsotti A.
        Admission C-reactive protein serum levels and survival in patients with acute myocardial infarction with persistent ST elevation.
        Coron Artery Dis. 2006; 17: 693-698
        • Mulvihill N.T.
        • Foley J.B.
        Inflammation in acute coronary syndromes.
        Heart. 2002; 87: 201-204
        • Liuzzo G.
        • Biasucci L.M.
        • Gallimore J.R.
        • Grillo R.L.
        • Rebuzzi A.G.
        • Pepys M.B.
        • Maseri A.
        The prognostic value of C-reactive protein and serum amyoid A protein in severe unstable angina.
        N Engl J Med. 1994; 331: 417-424
        • Lagrand W.K.
        • Visser C.A.
        • Hermens W.T.
        • Niessen H.W.
        • Verheugt F.W.
        • Wolbink G.J.
        • Hack C.E.
        C-Reactive protein as a cardiovascular risk factor: more than an epiphenomenon?.
        Circulation. 1999; 100: 96-102
        • De Servi S.
        • Mariani M.
        • Mariani G.
        • Mazzone A.
        C-Reactive protein increase in unstable coronary disease: cause or effect?.
        J Am Coll Cardiol. 2005; 46: 1496-1502